immunomic therapeutics crunchbase. J Immunol Res. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells. On behalf of the management team, I am pleased to welcome Ms. Harrison to ITI. The Phase 2 protocol will remain active, the existing Principal Investigators (PIs . Hershey, PA & Rockville, MD and Tokyo, Japan. This is the Immunomic Therapeutics company profile. Very family oriented. If you enjoy the challenge that goes naturally with being part of a high growth company, then a career with Immunomic Therapeutics may be just for you. HLB also secured an option to make further investment into the company in the months ahead. ITI-ID Candidate Multiple infectious diseases. Operating Status Active. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. Handled COVID very well. Last Funding Type Venture - Series Unknown. GBM patients white blood cells are removed, matured into dendritic cells and vaccinated against the pp65 viral protein, then returned to the patient. Those studies had enrolled all comers, and Bristol restricted Checkpoint-548's enrolment to patients carrying the MGMT methylation biomarker in . Immunomic Therapeutics considers applicants for all positions without regard to race, color, creed, religion, ancestry, national origin, age, gender identity, sex, marital status, sexual orientation, physical or mental disability, use of a guide dog or service animal, military/veteran status, citizenship status, basis of genetic information, or any other group protected by law. Contact Email info@immunic.de. Amy Conrad This is the Immunomic Therapeutics company profile. All answers shown come directly from Immunomic Therapeutics Reviews and are not edited or altered. Preclinical research data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. We currently have 4 wholly-owned oncology programs, with our lead program in Phase 2 clinical studies for GBM. Immunomic Therapeutics investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. Frans broad experience and deep knowledge in regulatory affairs will be a tremendous asset during a critical time for ITI, as we continue our interactions with the FDA and other key regulatory agencies regarding our clinical programs, stated William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. AAPL, FB, TWTR), Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. Coordinates: 245831.9N 1213154.0E. Company profile page for Immunomic Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information We now have a well-defined process to take things from ideation to in vivo animal proof of concept studies before handing them off to product development. April 23, 2020 04:00 PM Eastern Daylight Time. Prior to joining ITI, Ms. Harrison worked as a consultant for various biotechnology companies focused on oncology and infectious disease, leading client interactions with global regulatory authorities regarding product approvals and regulatory planning and implementation. The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced the appointment of Frances Harrison as Senior Vice President, Regulatory Affairs. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. 15010 Broschart Dr., Suite 110, Rockville, MD 20850. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy, and autoimmune diseases. Headquarters Location. 917-322-2571, Internet Explorer presents a security risk. Find More Contacts for Immunic Therapeutics, Edit Lists Featuring This Company Section, Immunic, Inc. Immunomic Therapeutics General Information. mcarey@rxir.com ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the close of a $61.3M financing led by HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs. 2017 Apr 15;23(8):1898-1909. ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients. 301-968-3501 The foundation of a successful company is only as strong as the quality of its employee team. Bard (Becton, Dickinson and Company). 1K followers 500+ connections. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. 717-327-1822, ITI Media: ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. Checkmate-548 was the most recent hope for Opdivo in glioblastoma following the failures, in 2017 and 2019 respectively, of Checkmate-143 in the second-line setting and Checkmate-498 in first-line. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of. Animal Health All. ITI-2000 provides an UNITE platform address for HPV+ cancers. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products . With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive. Contact Email info@immunomet.com. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . We are delighted to welcome Brian to the Immunomic team, said William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. ITI Company: Immunomic Therapeutics is a biotech company committed to patients. The work and relationships that Louise has fostered over the years position us for successful meetings in the future and I look forward to contributing meaningfully to the companys future regulatory interactions to further advance ITIs development programs utilizing the innovative and proprietary UNITE technology platform.. Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. Brians specific and deep knowledge of cell therapy manufacturing and operations will be invaluable as we prepare for phase 3 testing of ITI-1000, our lead dendritic cell therapy for the treatment of glioblastoma multiforme (GBM).. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. The majority of Merkel cell carcinomas (MCC), a rare but aggressive form of skin cancer, are associated with MCPyV infection, making LT an attractive target for this cancer vaccine. ROCKVILLE, Md.-- ( BUSINESS WIRE )--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . Find More Contacts for ImmunoMet Therapeutics, Edit Lists Featuring This Company Section, Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer, ImmunoMet Therapeutics Appoints Vincent ONeill Chief Medical Officer, Health Care Companies With Less Than $1M in Revenue (Top 10K), Pharmaceutical Companies With Fewer Than 1000 Employees (Top 10K), Southern US Companies With Less Than $50M in Revenue (Top 10K). Over 100 studies have been published on LAMP, ranging from those focused on the fundamental biology of lysosomal associated membrane protein to the immunobiology of novel vaccine candidates. Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body's natural biochemistry to develop vaccines that have the . January 30, 2015 - Immunomic Therapeutics, Inc. ("Immunomic Therapeutics "), a company developing next generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement for Japan to . ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. Pays for all health and welfare insurance premiums 100%. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. Request a free trial. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. Preclinical data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. GBM patients white blood cells are removed, matured into dendritic cells and vaccinated against the pp65 viral protein, then returned to the patient. It is interesting to note that the emerging market of brain tumor includes budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) and Ad-RTS-hIL-12 in combination with Veledimex . ITI-3000 is a plasmid DNA vaccine targeting the large T antigen (LT) of Merkel cell polyomavirus (MCPyV). ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. What is health insurance like at Immunomic Therapeutics. Their LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in . Senior Scientist/Scientist II, Formulation Development. As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. The first ITI oncology clinical program was born as a result of this decision and each subsequent asset in the pipeline represents a natural transition from this original point of entry into oncology. CONTACT US. ITI maintains its headquarters in Rockville, Maryland. UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform . ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. The Immunomic Therapeutics, Inc. team includes specialists in the areas of science, process development, engineering, production, marketing, finance, human resources, quality and regulatory, administrative support and more. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. ITI has entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers at Fred Hutchinson Cancer Research Institute, Johns Hopkins University of Medicine, and Duke University. Join to follow . Ms. Harrison earned a Bachelor of Science in Biochemistry from San Diego State University. Of special note are the following publications: To browse the literature, please see the curated list at PubMed. Immunic Therapeutics Investments & Acquisitions (2) Company Name Deal Date Deal Type Deal Size Industry Lead Partner; 00000 0000000: 12-Apr-2019: 0000000000: Drug Discovery: 000000 00: 4SC (immunology portfolio) 28-Sep-2016: The company held a successful pre-IND meeting earlier this year for ITI-1001 and expects to be able to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) by the end of 2020. Immunomic Therapeutics' continued investment in Process Development provides value in several ways. Share this article. But a few things must happen first. ITI-3000 is being tested in a Phase 1, open label, First in Human (FIH) study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with Merkel polyomavirus-positive Merkel cell carcinoma (MCC). all maps fatal bullet; who is running for senate in maryland 2022 In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. Immunomic Therapeutics' nucleic acid vaccines have the . Copied To explore Immunic Therapeutics's full profile, request access. Immunomic Therapeutics investigational UNITEplatform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. Concurrent with the financing, five (5) members from HLB Co., LTD will be joining the Immunomic Therapeutics Board of Directors. In this way, ITIs vaccines (DNA or RNA) have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. Our company has the capability to successfully plan, design and conduct clinical studies that enable us to establish POC in humans in a timely manner with the underlying capabilities to manufacture clinical trial supplies. For more information, please visit www.immunomix.com. 2015 Mar 19;519(7543):366-9. Our Company Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE ), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses Read More Our Focus ITI is . Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. The antigens mainly elicits TH1 response leading to cytokine release, development of cytotoxic CD8 T cells and memory CD4 T cells. Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the. Claim your Free Employer Profile. Su Y et al., Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: A phase I study. Founded Date 2015. Clin Cancer Res. amy@juniper-point.com Curr Opin Immunol. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. -Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of opportunities for its UNITE nucleic acid platform-. Mr. Stamper holds a Master of Biotechnology Enterprise and Entrepreneurship Degree (MBEE) from Johns Hopkins University, a Master of Science Degree in Biologics Engineering from Purdue University, and a Bachelor of Science Degree in Biochemistry from Indiana University. Be sure to include your name, the Job Code of the job you are interested in, and the accommodation you are seeking. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. November 30, 2021, 7:01 PM UTC. The company is developing three small molecule products; its lead development program, IMU-838, a selective . Immunomic Therapeutics (ITI) is a clinical stage biotechnology company pioneering investigational technologies that have the potential to alter how immunotherapy is used for cancer, allergies, and animal health. 2016;2016:4857869. It is one of the few malignancies for which incidence approximates prevalence, as patients almost always . ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). Where the organization is headquartered (e.g. Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. Prior to joining ITI, Mr. Stamper held director roles in manufacturing at Kite Pharma, a global biopharmaceutical company whose focus is cell therapy to treat and cure cancer. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Description. Prior to her role at BTG, she held senior regulatory positions at a variety of companies specializing in therapeutics for oncology, respiratory, neurology, regenerative medicine, orthopedics and cardiovascular disease including Life Cell Corporation (Allergan), Alphatec Spine, Covidien (Medtronic), Lumenis LTD, and C.R. 858-366-3243, Internet Explorer presents a security risk. View contacts for Immunic Therapeutics to access new leads and connect with decision-makers. Animal Health All. Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. We provide a professional and challenging work environment . The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. If you enjoy the challenge that goes naturally with being part of a high growth company, then a career with Immunomic Therapeutics, Inc. may be just for you. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. She succeeds Louise Peltier, Vice President of Regulatory Affairs, who retired on August 31, 2022. Jan 2006 - Present17 years 2 months. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI-2000 provides an UNITE platform address for HPV+ cancers. Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company revolutionizing the study of the Lysosomal Associated Membrane . ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients. Due to the volume of inquiries received, we regret that we cannot contact all applicants personally. Clin Cancer Res 2020;26:5297303, Batich K.A.,Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. 438 followers 429 connections. Email credentials to careers@immunomix.com. November 20, 2020-- Immunomic Therapeutics (ITI) and CoImmune Therapeutics have entered into a license agreement for ITI to use CoImmune's proprietary dendritic cell process for certain ITI cell therapy vaccine programs. Immunomic Therapeutics, Inc. Harnessing the immune system to achieve deep and durable clinical responses in cancer. People with disabilities who need a reasonable accommodation to apply or compete for employment with Immunomic Therapeutics may request such accommodation(s) by sending an e-mail to: careers@immunomix.com. 2017 Aug;47:85-92. All content is posted anonymously by employees working at Immunomic Therapeutics. Ms. Harrison brings to the company more than 30 years of experience in global regulatory strategies and submissions, interactions, intelligence and advocacy. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. Melissa Kemp Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. The Company has built a large pipeline from UNITE with six oncology programs and two allergy programs. They have a proven track record of success in Asia and share our commitment and passion for developing best-in-class therapies for cancer and other serious diseases, said Dr. William Hearl, CEO of Immunomic Therapeutics. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in this tumor type and others. Contacts ITI Company Contact: Melissa Kemp mkemp@immunomix.com 301-968-3501 ITI Media Contact: Melody Carey mcarey@rxir.com 917-322-2571 Leveraging our geographically precise solutions (GPS) platform, we are building a pipeline of tumor-activated cytokine and checkpoint inhibitor immunotherapies to treat cancer. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). View contacts for ImmunoMet Therapeutics to access new leads and connect with decision-makers. Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines. The New Taipei Municipal Hsin Tien Senior High School ( Chinese: ) is a senior high school in Xindian District, New Taipei, Taiwan which was founded in 1992. Jan 30, 2015. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural . ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. We are also collaborating with academic centers and biotechnology companies to study the use of the UNITE platform in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma. Immunomic Therapeutics, Inc. | 2,335 followers on LinkedIn. Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. Melody Carey Announces Proposed Public Offering of Common Stock, Northeastern US Companies With Fewer Than 1000 Employees (Top 10K), Companies With Fewer Than 100 Employees (Top 10K), United States Companies that Exited (Top 10K), Greater New York Area Biotechnology Companies. ROCKVILLE, Md., October 10, 2022--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . Immunomic Therapeutics, Inc. Biotechnology Research Rockville, MD 2,335 followers A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms At ITI, our success is based in great part on our ability to attract and retain the best, creative, talented, motivated and productive employees throughout our organization. This feature is in beta and may change with future updates. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. Today, Brian Stamper, VP, Immunomic Therapeutics, will participate at #MTC's Annapolis Day 2023. Active, Closed, Last funding round type (e.g. As a result, we make a significant investment in our employees through our Compensation, Health and Wellness, Retirement and Disability and Career Development programs. Developer of lysosomal-associated membrane protein (LAMP)-based vaccines designed to use immunotherapy to treat cancer, allergies, and animal health. Melssen M.,Vaccines targeting helper T cells for cancer immunotherapy. Sia Anagnostou Immunomic Therapeutics' investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITI's proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale.

Rusty Coones Wrestler, How To Copy Image From Canva To Powerpoint, Articles I